Epidemiological landscape of esophageal cancer in Asia: Results from GLOBOCAN 2020

Author:

Zhu Hongcheng1234ORCID,Wang Zezhou25,Deng Bingbin6,Mo Miao25,Wang Honggang7,Chen Ke28,Wu Haoxuan29ORCID,Ye Ting29,Wang Boyan1234,Ai Dashan1234ORCID,Hao Shennan1234,Tseng Ihsuan1234,Zhao Kuaile1234

Affiliation:

1. Department of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai China

2. Department of Oncology, Shanghai Medical College Fudan University Shanghai China

3. Shanghai Clinical Research Center for Radiation Oncology Shanghai China

4. Shanghai Key Laboratory of Radiation Oncology Shanghai China

5. Department of Cancer Prevention Fudan University Shanghai Cancer Center Shanghai China

6. Department of Radiotherapy and Oncology The Second Affiliated Hospital of Soochow University Suzhou China

7. Department of Gastroenterology The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University Huai'an China

8. Department of Endoscopy Fudan University Shanghai Cancer Center Shanghai China

9. Department of Thoracic Surgery Fudan University Shanghai Cancer Center Shanghai China

Abstract

AbstractBackgroundEsophageal cancer (EC) is a global health problem. Asia represents a huge burden of EC globally, and incidence and mortality vary considerably across different Asian regions.MethodsData on incidence, mortality, and preference were extracted from GLOBOCAN 2020. Age‐standardized incidence and mortality rates were calculated overall by sex, age, country, region, and continent. The predicted burden of incidence and mortality in 2040 was calculated based on global demographic projections.ResultsIt was estimated there were 481 552 new cases of and 434 363 deaths from EC in Asia in 2020, accounting for 79.7% and 79.8% of world EC cases and deaths, respectively. EC incidence and mortality in Asia ranked the highest among all continents. Eastern Asia represents the highest age‐standardized world incidence rate (ASWIR) of 12.3 per 100 000 for all Asian regions. Western Asia represents the lowest ASWIR of 1.7 per 100 000, accounting for 0.7% of the globe. There exist obvious differences in epidemiological features in Asian countries, including incidence, mortality, prevalence, and mortality incidence ratio. There is forecast to be up to 781 000 new cases of EC in Asia by 2040, with increasing rates of 63% for incidence and 72% for mortality from 2020.ConclusionsAsia has an increasing number of EC cases and deaths. Strategies for targeting in high‐incidence areas, the elderly, and survival should be prioritized to reduce the global EC burden, especially in low‐ and middle‐income countries in Asia.

Funder

Chinese Society of Clinical Oncology

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3